Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Benign Prostatic Hyperplasia

A Pharmacoeconomic Perspective

  • Review Article
  • Pharmacoeconomics
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Men with moderate symptoms of benign prostatic hyperplasia (BPH) are the best candidates for medical treatment, while surgery is usually indicated for patients with severe symptoms. Men with mild symptoms do not usually need treatment, but they might be re-evaluated annually if desirable.

Finasteride, which produces selective hormonal deprivation, is now established as a well tolerated drug for the long term medical therapy of BPH. Recent studies suggest that finasteride is most effective in men with large prostates (>40ml), and the drug should probably be reserved for these patients. α-Blockers work in men with small or large prostates, and their rapid onset of action facilitates the identification of responders. α-Blockers are more effective than finasteride during the first year of treatment, but only finasteride induces regression of the prostate and offers increased efficacy over time.

Even if drug therapy reduces the need for prostate surgery, the total economic cost of BPH treatment is likely to rise because of the increasing application of medical treatment. The magnitude of this increase depends largely on what percentage of the male population embark on long term therapy, at what age treatment is started, and how successful it is. At present, the answers to these questions are largely unknown. The personal economic expenses for men who begin long term medical therapy will probably be an important factor in deciding how common drug treatment for BPH will become in the future. For many men, the main benefit of drug treatment will be the relief of urinary symptoms, but whether this improvement is substantial enough to improve their overall quality of life has not yet been clearly demonstrated in controlled studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–9

    PubMed  CAS  Google Scholar 

  2. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990; 16: 39–48

    Article  PubMed  CAS  Google Scholar 

  3. Glynn RJ, Campion EW, Bouchard GR, et al. The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 1985; 121: 78–90

    PubMed  CAS  Google Scholar 

  4. Arrighi HM, Metter EJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991; 38 Suppl. 1: 4–8

    Article  PubMed  CAS  Google Scholar 

  5. Jensen KM-E, Jørgensen JB, Mogensen P, et al. Some clinical aspects of uroflowmetry in elderly males: a population survey. Scand J Urol Nephrol 1986; 20: 93–9

    Article  PubMed  CAS  Google Scholar 

  6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71

    Article  PubMed  CAS  Google Scholar 

  7. Jolleys JV, Donovan JL, Nanchahal K, et al. Urinary symptoms in the community: how bothersome are they? Br J Urol 1994; 74: 551–5

    Article  PubMed  CAS  Google Scholar 

  8. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl 1989; 2: 69–77

    Article  PubMed  CAS  Google Scholar 

  9. Abrams P. New words for old: lower urinary tract symptoms for ‘prostatism’. BMJ 1994; 308: 929–30

    Article  PubMed  CAS  Google Scholar 

  10. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595–600

    Article  PubMed  CAS  Google Scholar 

  11. Sagnier P-P, Girman CJ, Garraway M, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15–20

    PubMed  CAS  Google Scholar 

  12. Moon TD, Brannan W, Stone NN, et al. Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. J Urol 1994; 152: 1498–1500

    PubMed  CAS  Google Scholar 

  13. Boyle P, Maisonneuve P, Steg A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 1996; 155: 176–80

    Article  PubMed  CAS  Google Scholar 

  14. Ekman P. BPH epidemiology and risk factors. Prostate 1989; 2 Suppl. 2: 23–31

    Article  PubMed  CAS  Google Scholar 

  15. Graversen PH, Gasser TC, Wasson JH. Controversies about indications for transurethral resection of the prostate. J Urol 1989; 141: 475–81

    PubMed  CAS  Google Scholar 

  16. Barry MJ, Fowler FJ, O’Leary MP, et al. The measurement committee of the American Urological Association: the American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549–57

    PubMed  CAS  Google Scholar 

  17. Chappie CR, Noble JG, Milroy EJG. Comparative study of selective α1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993; 72: 822–5

    Article  Google Scholar 

  18. Guess HA, Jacobsen SJ, Girman CJ, et al. The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia. Med Care 1995; 33: AS26–35

    PubMed  CAS  Google Scholar 

  19. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243–7

    PubMed  CAS  Google Scholar 

  20. Schatzl G, Madersbacher S, Marberger M. The postoperative morbidity of transurethral resection of the prostate (TUR/P) and of four minimally invasive treatment alternatives [abstract no. 389]. J Urol 1996; 155: 408A

    Google Scholar 

  21. Kaplan SA. Benign prostatic hyperplasia — are we too ‘hot’ on new therapies? [editorial] J Urol 1996; 156: 426–7

    Article  PubMed  CAS  Google Scholar 

  22. Rittmaster RS. Finasteride. N Engl J Med 1994; 330: 120–5

    Article  PubMed  CAS  Google Scholar 

  23. Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 1995; 27: 267–73

    PubMed  CAS  Google Scholar 

  24. McConnell JD, for the Benign Prostatic Hyperplasia Guideline Panel. Clinical practice guidelines: quick reference guide for clinicians. Benign prostatic hyperplasia: diagnosis and treatment. Am J Fam Phys 1994; 49: 1157–65

    Google Scholar 

  25. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–9

    PubMed  CAS  Google Scholar 

  26. Gee WF, Holtgrewe HL, Albertsen PC, et al. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 1995; 154: 205–6

    Article  PubMed  CAS  Google Scholar 

  27. Janknegt RA. Summary: perspectives on the management of benign prostatic hyperplasia. Scand J Urol Nephrol 1995; 29: 35–6

    Google Scholar 

  28. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923–34

    Article  PubMed  CAS  Google Scholar 

  29. Beisland HO, Binkowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271–7

    PubMed  CAS  Google Scholar 

  30. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993; 46: 177–208

    Article  PubMed  CAS  Google Scholar 

  31. Yu H-J, Chiu T-Y, Lai M-K. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. J Formos Med Assoc 1995; 94: 37–41

    PubMed  CAS  Google Scholar 

  32. Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation. Br J Urol 1992; 70: 65–72

    Article  PubMed  CAS  Google Scholar 

  33. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91

    Article  PubMed  CAS  Google Scholar 

  34. Stoner E, and the Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–9

    Article  Google Scholar 

  35. Lepor H, Wiliford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9

    Article  PubMed  CAS  Google Scholar 

  36. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631–7

    Article  PubMed  CAS  Google Scholar 

  37. Lepor H. Long-term evaluation of tamsulosin, a prostate selective alpha1 antagonist [abstract no. 1099]. J Urol 1996; 155: 585A

    Article  Google Scholar 

  38. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159–68

    Article  PubMed  CAS  Google Scholar 

  39. Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience. Eur Urol 1995; 28: 304–9

    PubMed  CAS  Google Scholar 

  40. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405

    Article  PubMed  CAS  Google Scholar 

  41. Walsh PC. Treatment of benign prostatic hyperplasia [editorial]. N Engl J Med 1996; 335: 586–7

    Article  PubMed  CAS  Google Scholar 

  42. Monda JM, Oesterling JE. Subspecialty clinics: urology. Medical treatment of benign prostatic hyperplasia: 5α-reductase inhibitors and α-adrenergic antagonists. Mayo Clin Proc 1993; 68: 670–9

    PubMed  CAS  Google Scholar 

  43. Fabricius PG, Weizert P, Dunzendorfer U, et al. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Prostate Suppl 1990; 3: 85–93

    Article  PubMed  CAS  Google Scholar 

  44. Thomas S, for the ITT Study Group. The international terazosin trial (ITT) — a double-blind, placebo-controlled randomized withdrawal study of the symptomatic treatment of BPH [abstract no. 236]. Proceedings of the 11th Congress of the European Association of Urology. Berlin 1994 Jul 13–16: 124

  45. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599–604

    Article  PubMed  CAS  Google Scholar 

  46. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467–74

    PubMed  CAS  Google Scholar 

  47. Lepor H, on behalf of the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406–13

    Article  PubMed  CAS  Google Scholar 

  48. Kane MM, Fields DW, Vaughan Jr ED. Medical management of benign prostatic hyperplasia. Urology 1990; 36: 5–12

    Article  PubMed  CAS  Google Scholar 

  49. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297–307

    Article  PubMed  CAS  Google Scholar 

  50. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995; 45: 258–64

    Article  PubMed  CAS  Google Scholar 

  51. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154: 1779–82

    Article  PubMed  CAS  Google Scholar 

  52. Jønler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994; 47: 66–81

    Article  PubMed  Google Scholar 

  53. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31–7

    Article  PubMed  CAS  Google Scholar 

  54. Guess HA, Gormley GJ, Stoner E, et al. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155: 3–9

    Article  PubMed  CAS  Google Scholar 

  55. Williford WO, Lepor H, Dixon CM, et al. Serum PSA levels after 5 weeks of therapy with finasteride, terazosin, combination, and placebo: results of the VA Cooperative Study #359 [abstract no. 890]. J Urol 1996; 155: 533A

    Google Scholar 

  56. Abbou CC, Hozneck A, McCarthy C. Alfuzosin, a uroselective α1 blocker, versus pygeum africanum, a plant extract: a randomized controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH) [abstract no. 241]. Eur Urol 1996; 30 Suppl. 2: 77

    Google Scholar 

  57. Carraro JC, Raynaud JP, Chisholm GD. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients [abstract no. 240]. Eur Urol 1996; 30 Suppl. 2: 76

    Google Scholar 

  58. Plosker GL, Brogden RN. Serenoa repens (Permixon®): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996 Nov; 9: 379–95

    Article  PubMed  CAS  Google Scholar 

  59. Stoner E, on behalf of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–94

    Article  PubMed  CAS  Google Scholar 

  60. Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145–54

    PubMed  CAS  Google Scholar 

  61. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 29: 7–12

    Google Scholar 

  62. Lowe F, Tuttle J, Marks S, et al. Blood pressure effects of men with prostatism concurrently treated with antihypertensives and terazosin [abstract no. 176]. J Urol 1995; 153: 272A

    Google Scholar 

  63. Titmarsh S, Monk P. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987; 33: 460–77

    Article  Google Scholar 

  64. Ahlstrand C, Carlsson P, Jönsson B. Estimated total costs of treating benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1995; 29: 57–63

    Article  PubMed  CAS  Google Scholar 

  65. Carson CC, Singla A, Rutledge R. Benign prostatic hyperplasia, impact of medical therapy on TURP: a statewide population-based analysis of 26625 patients [abstract no. 1481]. J Urol 1996; 155: 681A

    Article  Google Scholar 

  66. Holtgrewe HL, Ackermann R, Bay-Nielsen H, et al. The economics of BPH. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 1993 Jun 27–30; Paris. Jersey: Scientific Communication International Ltd, 1993: 37–45

  67. Hill SJ, Lawrence SL, Lepor H. New use for alpha-blockers: benign prostatic hyperplasia. Am Fam Physician 1994; 49: 1885–8

    PubMed  CAS  Google Scholar 

  68. Gibbons RP, McNicholas TA, Koshiba K, et al. Surgical and laser treatment. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 1993 Jun 27–30; Paris. Jersey: Scientific Communication International Ltd, 1993: 363–76

  69. Altwein JE. Introduction: the changing therapy of benign prostatic hyperplasia. Scand J Urol Nephrol 1995; 29: 1–6

    Google Scholar 

  70. Weis KA, Epstein RS, Huse DM, et al. The cost of prostatectomy for benign prostatic hyperplasia. Prostate 1993; 22: 225–34

    Article  Google Scholar 

  71. Russell DJ, Kaufman Jr RP, Cain MP. Medical management of benign prostatic hyperplasia (BPH) versus transurethral prostatectomy: the economic consequences [abstract no. 883]. J Urol 1993; 149: 433A

    Google Scholar 

  72. Lepor H. The role of alpha blockade in the therapy of benign prostatic hyperplasia. In: Lepor H, Lawson RK, editors. Prostate diseases. Philadelphia: WB Saunders, 1993: 170–81

    Google Scholar 

  73. Naslund MJ, Stitcher MF. Cost comparison of medical management and surgical prostatectomy for BPH [abstract no. 161]. J Urol 1994; 151: 268A

    Google Scholar 

  74. Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169–78

    Article  PubMed  CAS  Google Scholar 

  75. Naslund MJ. A new valuation model for BPH treatment from the employer and patient perspective [abstract no. 1483]. J Urol 1996; 155: 682A

    Google Scholar 

  76. Goluboff ET, Olsson CA. Urologists on a tightrope: coping with a changing economy. J Urol 1994; 151: 1–4

    PubMed  CAS  Google Scholar 

  77. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996; 155: 1311–16

    Article  PubMed  CAS  Google Scholar 

  78. Holtgrewe HL. Economics of benign prostatic hyperplasia. In: Kirby R, editor. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media, 1996: 527–36

    Google Scholar 

  79. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995; 155: 477–81

    Article  PubMed  CAS  Google Scholar 

  80. Lukacs B, McCarthy C, Thibault P. Twelve month assessment of long term health related quality of life (HRQOL) of 5849 patients suffering from benign prostatic hypertrophy (BPH) treated by an uroselective alpha 1 blocker alfuzosin [abstract no. 163]. J Urol 1994; 15L: 268A

    Google Scholar 

  81. Martelli A, Pacifico P, Casadei B, on behalf of the Italian Alfuzosin Co-Operative Group. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Eur Urol 1993; 24 Suppl. 1: 28–33

    PubMed  Google Scholar 

  82. Hillman AL, Schwartz JS, Willian MK, et al. The Hytrin community assessment trial (HYCAT): a randomized, placebo-controlled trial of the cost-effectiveness of Hytrin in the treatment of benign prostatic hyperplasia (BPH) [abstract no. 996]. J Urol 1995; 153: 477A

    Article  Google Scholar 

  83. Khoury S. Future directions in the management of benign prostatic hyperplasia. Br J Urol 1992; 70 Suppl. 1: 27–32

    Article  PubMed  Google Scholar 

  84. Robert M, Costa P, Bressolle F, et al. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol 1995; 75: 317–24

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Ullevaal University Hospital, 0407, Oslo, Norway

    Lars M. Eri & Kjell J. Tveter

Authors
  1. Lars M. Eri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kjell J. Tveter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eri, L.M., Tveter, K.J. Treatment of Benign Prostatic Hyperplasia. Drugs & Aging 10, 107–118 (1997). https://doi.org/10.2165/00002512-199710020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710020-00004

Keywords

Search

Navigation